Hers vs BreezeMeds: Wegovy and GLP-1 options compared
Comparing Hers vs BreezeMeds shows clear differences in FDA labeling, pricing transparency, and product formats. Early verdict: Hers emphasizes FDA-approved Wegovy® from $149/mo with no compounded medications and a membership requirement; BreezeMeds highlights injectable and oral GLP-1 options with injections starting at $199/mo and oral options from $399.
Key distinctions between Hers vs BreezeMeds
The most distinctive supported differences are: FDA-approved brand-name offering and membership requirement at Hers, variety of oral and injectable options at BreezeMeds, starting prices and price transparency, and statements on compounded medications and regulatory notes. Each section below compares these points directly.
1. FDA approval and compounded medication status
Hers: Offers FDA-approved Wegovy® and states it is not a compounded product. The source repeatedly identifies Wegovy® as brand-name semaglutide and emphasizes no compounded medications.
BreezeMeds: The site lists semaglutide and tirzepatide injections and oral options but does not present the same FDA labeling for a specific brand in the captured evidence. The provider notes that medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable.
2. Medication formats and options
Hers: Focused on FDA-approved Wegovy® and brand-name GLP-1s, with mentions of semaglutide and tirzepatide options appearing in pricing details.
BreezeMeds: Lists semaglutide injection, tirzepatide injection, oral semaglutide, and oral tirzepatide in the captured evidence. BreezeMeds explicitly displays oral options from $399 in the source material.
3. Pricing and membership notes
Hers: Shows Wegovy® pill from $149/mo and injectable from $199/mo in short headlines and long bullets. Detailed text states “From $149/mo” and includes a membership requirement: an active Hers Weight Loss Membership is required with a $39 first month then auto-renews at $149/month thereafter in the captured landing-page evidence. The source qualifies that price includes medication only if prescribed and that a prescription is not guaranteed.
BreezeMeds: Presents semaglutide injection from $199/mo, tirzepatide injection from $299, and oral semaglutide and oral tirzepatide displayed from $399. A separate $169 figure appears in the source material without a clear product association. The captured evidence also notes that fees and billing commitments were not fully visible.
4. Shipping, discreet delivery, and support
Hers: Emphasizes personalized care teams with ongoing dose check-ins and name-brand medication with no price markups in the captured content.
BreezeMeds: Highlights discreet home delivery and ongoing support. The source uses phrases like “Discreet Shipping” and “Discreet shipping to your door with ongoing support” in the captured landing-page evidence.
5. Availability and eligibility language
Both providers include clinician review and eligibility qualifiers in the captured text. Hers specifies not available in all 50 states and that treatment is available only when a licensed clinician determines it is medically appropriate. BreezeMeds captured evidence similarly states treatment is available only when a licensed clinician determines it is medically appropriate.
| Criteria | Hers | BreezeMeds |
|---|---|---|
| FDA-approved brand | Wegovy® explicitly FDA-approved; not compounded | Medication-specific approval status must be confirmed |
| Starting price (captured) | Wegovy® pill from $149/mo; injectable from $199/mo | Semaglutide injection from $199/mo; oral from $399 |
| Medication formats | Brand-name semaglutide; semaglutide and tirzepatide mentioned | Injectable and oral semaglutide and tirzepatide |
| Membership or fees | Active membership required; $39 first month then auto-renews at $149/mo according to captured evidence | Fees and billing commitments not fully visible; a $169 figure appears without clear product tie |
| Delivery and support | Personalized care team, ongoing dose check-ins | Discreet home delivery and ongoing support |
Compare Hers membership and plans
How to choose between Hers vs BreezeMeds
Use the comparison above to match the provider to your priorities. If FDA-approved brand-name Wegovy® and an explicit statement of no compounded medications matter, Hers is the supported choice in the captured evidence. If you prioritize having both injectable and oral GLP-1 formats explicitly listed, BreezeMeds is the supported choice in the captured evidence.
Explore BreezeMeds formats and pricing
Final take on Hers vs BreezeMeds
Hers vs BreezeMeds differs mainly on FDA-label clarity, membership requirements, and the presence of oral GLP-1 options in the captured evidence. Hers highlights FDA-approved Wegovy® starting at $149/mo with a required membership and no compounded medications. BreezeMeds lists injectable semaglutide from $199/mo and oral GLP-1s from $399 but the captured content leaves some pricing details and product ties less clear.
Choose Hers if you want FDA-approved Wegovy® with no compounded medications and are prepared for a membership requirement. Choose BreezeMeds if having injectable and oral semaglutide or tirzepatide options shown in the captured evidence is a priority.